Market Overview

Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference


Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global
leader in tubeless
insulin pump
technology with its Omnipod® Insulin
Management System (Omnipod System), today announced it will showcase its
recently FDA cleared Omnipod DASH™ Insulin Management System (Omnipod
DASH System), during the American Association of Diabetes Educators
meeting at the Baltimore Convention Center in Baltimore, Maryland on
August 17-20, 2018.

Insulet will feature its new, innovative Omnipod DASH System in a
variety of hands-on, interactive product demonstrations at its exhibit
booth (#611). The Company will also host a panel discussion and product
theater, the details for which are below.

Technology and Time in Range: The DASH Towards a Solution Panel

  • Thursday, August 16th, 7 – 9PM
  • Harbor Tower, Cook Commons Room, 100 International Drive, Baltimore, MD
  • Moderator: Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and
    Medical Director, Insulet
  • Panelists: Cari Berget, RN, MPH, CDE, Clinical Research Team Manager,
    University of Colorado Denver School of Medicine, Department of
    Pediatrics, Barbara Davis Center for Diabetes; Donna L. Jornsay, MS,
    BSN, RN, CPNP, CDE, CDTC, BC-ADM, Diabetes Educator and Nurse
    Consultant; Christel Aprigliano, CEO The Diabetes Collective and Vice
    President of DPAC; Caroline Hill, Podder, Pre-Med Student at Louisiana
    Tech University, College Diabetes Network Chapter President, Diabetes

The Omnipod DASH System: Simplifying Insulin Delivery for Your Patients
and Your Practice Product Theater:

  • Friday, August 17th, 12:15 – 1PM
  • Baltimore Convention Center, Exhibit Hall, Product Theater A
  • Presenter: Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and
    Medical Director, Insulet

"We are excited for the opportunity to introduce Omnipod DASH to the
diabetes educators, many of whom provided incredibly helpful input on
DASH's functionality and design at last year's AADE," said Bret
Christensen, Chief Commercial Officer. "We are committed to delivering
innovative products to the diabetes community to reduce the burden of
diabetes for both patients and clinicians. We are thrilled to present
DASH to the diabetes educator community so they can see firsthand how
our innovative product will help make diabetes a smaller part of their
patients' lives."

About Insulet Corporation:

Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its Pod, by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, more than 140,000 users across the globe rely on
Insulet's Omnipod Insulin Management System to bring simplicity and
freedom to their lives. For more information, please visit:

*On July 1, 2018, Insulet assumed direct operations of its Omnipod
Insulin Management System product line in Europe, including sales,
marketing, training and customer support activities. This allows Insulet
to be closer to the diabetes community and identify opportunities to
support European customer needs over the long-term, as Insulet does in
the United States and Canada.

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
"Risk Factors," and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. DASH, Omnipod and the Omnipod logo are
trademarks or registered trademarks of Insulet Corporation. All rights

View Comments and Join the Discussion!